The How And When Of Applying Sequencing To Clinical Diagnostics
Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing. As technology innovation continues, costs decrease, and the pace and scope of clinical genomic studies picks up, the notion of sequencing as the foundation for a clinical diagnostics platform is gaining more support. Delivering value to diagnostics customers ultimately may demand that instrument providers move downstream, involving themselves in data analysis and workflow and even test development, to prime the clinical market.
You may also be interested in...
A Researcher’s Hope For Sequencing: Rare Genetic Variants Yield New Drugs
Columbia University Professor Wendy Chung’s work on identifying the causative mutations underlying ultra-rare diseases such as hereditary pulmonary hypertension puts a real-world perspective on pharma’s increasing interest in genomic analysis as a tool for drug discovery.
Qiagen Moves Into Next-Gen Sequencing
Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.
Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF
After a few months of sometimes-testy back and forth, Illumina seemingly has successfully fended off Roche’s hostile offer. But Roche is unlikely to give up on the sequencing tool maker entirely.